Skip to main content
. Author manuscript; available in PMC: 2023 Mar 1.
Published in final edited form as: Exp Hematol. 2021 Dec 15;107:14–19. doi: 10.1016/j.exphem.2021.12.364

Figure 2. JAK2-V617F induces SLAMF7 expression and an intermediate monocyte phenotype in MPN patients.

Figure 2.

A. Marker gene expression UMAPs of the bone marrow monocyte compartment measured by scRNA-seq in 8 MPN patients. B. JAK2-WT (blue) and JAK2-V617F (red) transcripts detected in monocytes. C. UMAP of scRNA-seq data from monocytes colored by transcriptionally defined monocyte subset classifications. D. Fraction of CD14+ cells with a JAK2-WT or JAK2-mutant transcript detected by scRNA-seq that are classical, intermediate, or nonclassical monocytes. The monocyte subset definitions and color scheme are the same as in C. E. Differential expression analysis of monocytes from all 8 MPN patients, comparing cells with at least one mutant transcript detected to cells with a WT transcript detected. Ribosomal genes, antigen presentation genes, and proteasomal genes are colored in blue, green, and red, respectively. F-G. Flow cytometry and SLAMF7 staining of CD14+ cells from three MPN patients and three healthy controls. Gating scheme to identify SLAMF7 is shown in F, and the proportion of CD14+ cells expressing SLAMF7 is shown in G.